Blog

According to the latest market research study published by P&S Intelligence, the global insulin delivery devices market is poised for substantial growth, with projections indicating an increase from $21.4 billion in 2024 to $39.7 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.8%. This surge is primarily driven by technological advancements in diabetes care, a rising diabetic population, and heightened awareness about innovative insulin delivery methods. The International Diabetes Federation reported that in 2021, 537 million individuals aged 20–79 were living with diabetes globally, a number expected to reach 643 million by 2030 and 783.2 million by 2045. This escalating prevalence underscores the critical need for efficient and user-friendly insulin delivery devices.

Key Insights

Insulin Pens Lead the Market

Insulin pens are projected to account for approximately 50% of the market share in 2024. Their dominance is attributed to the increasing prevalence of diabetes and manufacturers' focus on expanding their presence in countries with large diabetic populations, such as China and India. Technological advancements and favorable medical reimbursements in developed regions further bolster their adoption.  

Reusable Pens Preferred

Within the insulin pens category, reusable pens hold the larger share, a trend expected to continue due to their user-friendly design that minimizes dosage errors.

Pharmacies as Primary Distribution Channels

Pharmacies dominate the distribution landscape, accounting for 55% of sales in 2024. This preference is mainly because patients often choose to purchase these devices from pharmacies.

E-Commerce on the Rise

The e-commerce segment is anticipated to experience the highest CAGR of 11.5% during the forecast period. Online pharmacies offer consumers the convenience of comparing products, electronic payments, home delivery, and access to discounts and promotional offers.

Home-Use Devices Gaining Traction

There's a significant shift toward home infusion therapy, driven by the emphasis on cost-effective healthcare and patient convenience. Advanced insulin delivery devices, particularly insulin pumps, are gaining acceptance among diabetic patients for accurate dosage administration throughout the day.

Technological Innovations Fueling Growth​

Continuous technological advancements in insulin delivery devices, such as insulin pens, pumps, and inhalers, are enhancing their acceptance. These devices offer accurate insulin dosage, helping maintain optimal blood glucose levels. For instance, insulin pens are less time-consuming compared to syringes with vials and pose a minimal risk of dosage inaccuracies.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/insulin-delivery-devices/report-sample

North America at the Forefront

North America is expected to maintain its position as the largest market for insulin delivery devices through 2030. This is due to factors such as the rising prevalence of diabetes, favorable reimbursement scenarios, increasing venture capital investments, and approvals from the U.S. Food and Drug Administration (FDA) for newer insulin delivery devices, enhancing their availability.

Asia-Pacific Exhibiting Rapid Growth

The Asia-Pacific region is projected to be the fastest-growing market, driven by the increasing diabetic population, rising awareness about advanced diabetes care devices, and improving healthcare infrastructure.

Competitive Landscape

The market is consolidated, with established players holding significant shares due to high entry barriers, such as substantial investments required for developing devices that comply with stringent safety and efficacy regulations. Key players include Becton, Dickinson and Company; Medtronic plc; Tandem Diabetes Care Inc.; Biocon Ltd.; Eli Lilly and Company; Insulet Corporation; Novo Nordisk A/S; Sanofi S.A.; Ypsomed Holding AG; F. Hoffmann-La Roche Ltd.; Wockhardt Ltd.; and B. Braun Melsungen AG.  

The insulin delivery devices market is on a robust growth trajectory, propelled by technological innovations, evolving patient preferences, and a global increase in diabetes prevalence. Stakeholders are focusing on enhancing device accessibility, user-friendliness, and integration with digital platforms to improve diabetes management outcomes.